CTAD 2026 Poster Presentations

Learn about the latest study findings from Linus Health

Explore Linus Health’s poster presentations at CTAD. View the presentation schedule below for dates, times, and details.

Boston Massachusetts Financial District

November 16-17


IMAGING (MRI & PET)

Predicting Amyloid PET Positivity from a Brief Digital Cognitive Assessment in Memory Clinic Patients

Dr. Ali Jannati
Director of Cognitive Science, Linus Health

Location: P090

Key takeaways:

  • Memory measures from the 7-minute Linus Cognitive Profile helped distinguish patients with and without amyloid buildup in a memory clinic study.
  • These early findings suggest the assessment could help guide further testing for Alzheimer’s disease, pending confirmation in larger studies.

ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS 

Improved Performance and Fairness of Dementia Risk Stratification from Claims Data with Machine Learning

Dr. Daniel Schulman
Lead Data Scientist/Biostatistician

Location: P122

Key takeaways:

  • The updated Radar model used Medicare claims data to better predict who would receive a dementia diagnosis and showed more consistent performance across age groups than earlier models.
  • This approach could help health systems and researchers prioritize people for cognitive screening and clinical trial recruitment.

November 19


COGNITIVE AND FUNCTIONAL OUTCOMES

Measuring meaningful benefits across cultures in AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics

Dr. Ali Jannati
Director of Cognitive Science, Linus Health

Location: P409

Key takeaways:

  • Japanese patients with early Alzheimer’s disease generally found ePSOM acceptable and relevant to their lives, with most receiving help completing it.
  • The findings support further use and evaluation of ePSOM across cultures to bring patients’ personal priorities into Alzheimer’s research.

COGNITIVE AND FUNCTIONAL OUTCOMES

Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment

Dr. Ali Jannati
Director of Cognitive Science, Linus Health

Location: P429

Key takeaways:

  • Linus Cognitive Assess, formerly Digital Clock and Recall, showed reliable performance across research studies and practical use in routine care.
  • Its AI-derived Cognition Score improved detection of cognitive impairment compared with the original score in a research study, supporting its use in primary care and clinical trial prescreening.

COGNITIVE AND FUNCTIONAL OUTCOMES

A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care

Dr. Ali Jannati
Director of Cognitive Science, Linus Health

Location: P428

Key takeaways:

  • In a research study, using the Linus Cognitive Assess, formerly Digital Clock and Recall, as the first screening step identified more mild dementia cases than the Mini-Cog alone.
  • This approach also produced fewer false alarms, suggesting potential to improve screening in primary care. Confirmation in clinical practice is needed.

COGNITIVE AND FUNCTIONAL OUTCOMES

Understanding Cognitive Impairment Through Analysis of Process Metrics Derived from the Digital Assessment of Cognition

Dr. Tanya Talkar
Senior Data Scientist 

Location: P449

Key takeaways:

  • How people respond, including their timing, word choices, and errors, provided additional insight into differences between normal cognition, mild cognitive impairment, and dementia.
  • These measures improved the ability to distinguish among the groups compared with using age alone.

Curious about our solutions for clinical trials? 

Take a closer look at our platform to learn more about the suite of digital assessments Linus offers.